A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

September 18, 2020

Study Completion Date

August 18, 2021

Conditions
Knee Osteoarthritis
Interventions
DRUG

Placebo

Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)

DRUG

SM04690

Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24. (In the extension phase, healthcare professional-administered intra-articular injections; first performed at Week 52 and second at Week 76.)

Trial Locations (13)

29406

Research Site, Charleston

30189

Research Site, Woodstock

32132

Research Site, Edgewater

33143

Research Site, Miami

45246

Research Site, Cincinnati

64114

Research Site, Kansas City

76904

Research Site, San Angelo

85018

Research Site, Phoenix

85053

Research Site, Phoenix

87102

Research Site, Albuquerque

91303

Research Site, Canoga Park

91941

Research Site, La Mesa

95628

Research Site, Carmichael

Sponsors
All Listed Sponsors
lead

Biosplice Therapeutics, Inc.

INDUSTRY